Institutional members access full text with Ovid®

Cancer Drug Lenalidomide May Increase Risk of Second Primary Malignancies

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: September 2012 - Volume 112 - Issue 9 - p 24
doi: 10.1097/01.NAJ.0000418924.37977.af
Drug Watch

* The label of lenalidomide (Revlimid) now carries a warning that patients taking the drug for multiple myeloma have a heightened risk of new primary cancers.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2012 Lippincott Williams & Wilkins, Inc.